Xvivo Perfusion AB (publ) (STO:XVIVO)

Market Cap	9.27B -6.7%
Revenue (ttm)	834.53M -2.4%
Net Income	73.86M -46.1%
EPS	2.34 -45.9%
Shares Out	31.50M
PE Ratio	125.66
Forward PE	65.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,603
Average Volume	68,264
Open	297.20
Previous Close	294.40
Day's Range	291.40 - 297.20
52-Week Range	160.00 - 322.40
Beta	1.42
RSI	61.08
Earnings Date	Jul 14, 2026

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 199
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XVIVO

Financial Performance

In 2025, Xvivo Perfusion AB's revenue was 812.17 million, a decrease of -1.25% compared to the previous year's 822.42 million. Earnings were 25.16 million, a decrease of -85.39%.